Incidence Rates Table
Incidence Rate Report by State
Lung & Bronchus (Late Stage^), 2017-2021
All Races (includes Hispanic), Both Sexes, All Ages
Sorted by Rate
State
|
Age-Adjusted Incidence Rate † cases per 100,000 (95% Confidence Interval) 
|
CI*Rank ⋔ (95% Confidence Interval) 
|
Average Annual Count
|
Percent of Cases with Late Stage
|
|---|---|---|---|---|
| US (SEER+NPCR) 1 | 34.3 (34.2, 34.4) | N/A | 140,561 | 64.9 |
| Puerto Rico 6 | 7.5 (7.2, 7.9) | N/A | 342 | 49.2 |
| Utah 3 | 17.0 (16.4, 17.7) | 50 (50, 50) | 492 | 69.0 |
| New Mexico 3 | 19.5 (18.8, 20.3) | 49 (49, 49) | 554 | 60.1 |
| Colorado 6 | 23.3 (22.7, 23.8) | 48 (47, 48) | 1,505 | 62.5 |
| California 3 | 24.5 (24.3, 24.7) | 47 (46, 47) | 11,010 | 67.1 |
| Wyoming 6 | 24.9 (23.3, 26.6) | 46 (43, 48) | 185 | 63.4 |
| Arizona 6 | 25.4 (24.9, 25.9) | 45 (43, 46) | 2,412 | 60.1 |
| Nevada 6 | 26.0 (25.2, 26.7) | 44 (43, 46) | 984 | 59.1 |
| District of Columbia 6 | 26.7 (25.0, 28.6) | 43 (41, 47) | 179 | 59.9 |
| Hawaii 3 | 28.5 (27.4, 29.6) | 42 (39, 43) | 578 | 71.5 |
| Montana 6 | 28.8 (27.6, 30.1) | 41 (38, 43) | 447 | 62.8 |
| Texas 3 | 29.4 (29.2, 29.7) | 40 (38, 42) | 8,730 | 64.6 |
| Oregon 6 | 29.6 (28.9, 30.2) | 39 (38, 42) | 1,681 | 62.2 |
| Idaho 3 | 30.6 (29.5, 31.6) | 38 (34, 41) | 675 | 68.1 |
| Washington 5 | 31.4 (30.9, 32.0) | 37 (34, 38) | 2,914 | 64.6 |
| Maryland 6 | 31.8 (31.2, 32.4) | 36 (33, 38) | 2,455 | 64.1 |
| New Jersey 3 | 31.9 (31.4, 32.4) | 35 (33, 37) | 3,781 | 65.1 |
| Nebraska 6 | 32.4 (31.3, 33.4) | 34 (30, 38) | 777 | 62.1 |
| Minnesota 6 | 32.8 (32.2, 33.4) | 33 (30, 35) | 2,351 | 60.6 |
| Virginia 6 | 33.1 (32.6, 33.6) | 32 (30, 34) | 3,535 | 64.7 |
| New York 3 | 33.5 (33.2, 33.8) | 31 (28, 33) | 8,734 | 62.7 |
| Massachusetts 3 | 34.0 (33.5, 34.5) | 30 (25, 32) | 3,118 | 60.2 |
| Alaska 6 | 34.4 (32.4, 36.5) | 29 (18, 36) | 253 | 66.2 |
| Kansas 6 | 34.6 (33.7, 35.5) | 28 (22, 31) | 1,262 | 66.5 |
| Florida 6 | 34.6 (34.3, 34.9) | 27 (23, 30) | 11,291 | 63.3 |
| Connecticut 3 | 34.7 (34.0, 35.5) | 26 (22, 30) | 1,687 | 63.0 |
| Vermont 6 | 34.7 (33.0, 36.5) | 25 (19, 34) | 332 | 64.1 |
| Alabama 6 | 35.2 (34.6, 35.9) | 24 (21, 29) | 2,359 | 60.6 |
| Rhode Island 6 | 35.7 (34.3, 37.1) | 23 (17, 30) | 526 | 59.3 |
| Delaware 6 | 35.9 (34.4, 37.3) | 22 (17, 30) | 512 | 64.2 |
| South Dakota 6 | 36.5 (34.9, 38.2) | 21 (14, 29) | 414 | 66.8 |
| North Dakota 6 | 36.7 (34.9, 38.5) | 20 (14, 29) | 336 | 65.5 |
| Wisconsin 6 | 36.9 (36.3, 37.5) | 19 (17, 23) | 2,920 | 66.4 |
| Pennsylvania 6 | 37.5 (37.1, 37.9) | 18 (16, 21) | 6,864 | 64.8 |
| South Carolina 6 | 37.6 (37.0, 38.3) | 17 (15, 21) | 2,630 | 64.7 |
| New Hampshire 6 | 38.1 (36.8, 39.4) | 16 (13, 22) | 756 | 64.6 |
| Illinois 3 | 38.4 (37.9, 38.8) | 15 (14, 17) | 6,143 | 66.1 |
| Georgia 3 | 38.9 (38.4, 39.4) | 14 (13, 16) | 4,758 | 69.2 |
| Michigan 6 | 39.5 (39.0, 40.0) | 13 (12, 15) | 5,396 | 67.3 |
| Oklahoma 6 | 40.5 (39.7, 41.3) | 12 (11, 13) | 1,976 | 64.3 |
| Ohio 6 | 41.9 (41.5, 42.4) | 11 (8, 11) | 6,615 | 65.4 |
| North Carolina 6 | 42.0 (41.5, 42.5) | 10 (8, 11) | 5,597 | 67.3 |
| Iowa 3 | 42.0 (41.2, 43.0) | 9 (7, 12) | 1,766 | 69.2 |
| Arkansas 6 | 42.7 (41.7, 43.6) | 8 (5, 11) | 1,690 | 62.6 |
| Tennessee 6 | 43.5 (42.9, 44.2) | 7 (4, 8) | 3,882 | 64.2 |
| Louisiana 3 | 43.8 (43.0, 44.6) | 6 (4, 8) | 2,540 | 72.1 |
| Missouri 6 | 43.9 (43.2, 44.5) | 5 (4, 8) | 3,570 | 65.3 |
| Maine 6 | 44.4 (43.1, 45.7) | 4 (3, 8) | 947 | 65.7 |
| Mississippi 6 | 46.6 (45.6, 47.6) | 3 (3, 4) | 1,759 | 67.8 |
| West Virginia 6 | 52.0 (50.8, 53.3) | 2 (2, 2) | 1,405 | 68.0 |
| Kentucky 3 | 57.7 (56.9, 58.6) | 1 (1, 1) | 3,392 | 68.5 |
| Indiana 6 |
|
N/A |
|
|
Notes:
Created by statecancerprofiles.cancer.gov on 05/21/2025 3:05 pm.
State Cancer Registries may provide more current or more local data.
† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.
Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.
^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.
Data not available for this combination of data selections.
1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
3 Source: SEER November 2023 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2023 submission).
Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.
Created by statecancerprofiles.cancer.gov on 05/21/2025 3:05 pm.
State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.
† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.
Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.
^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.
Data not available for this combination of data selections.
1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
3 Source: SEER November 2023 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2023 submission).
Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.